BODI Bodisen

RNS Number:0382C
Bodisen Biotech Inc
14 August 2007

14 August 2007

                             Bodisen Biotech, Inc.

     BODISEN BIOTECH SUFFERS PRODUCT AND RAW MATERIAL LOSS DUE TO FLOODING

Bodisen Biotech, Inc. (the "Company") (London AIM:BODI, Pink Sheets:BBCZ,
website: www.bodisen.com) announced today that flooding due to a significant
thunderstorm caused uninsured loss of product and raw materials at its
facilities in Yangling. Preliminary estimates by the Company put those losses at
up to 1.5 million USD.

The storm, which struck on August 8, caused massive flooding and power outages
in many areas of Shaanxi province, was described in local press accounts as the
worst in ten years.  Despite heroic efforts by employees at both of the
Company's Yangling facilities to limit damages, substantial loss was suffered.
Despite this event, production continues at both facilities without significant
disruption of operations after the storm passed. Photographs and local press
accounts of the storm and its aftermath may be accessed at the Company's
website:  www.bodisen.com at the tab marked "storm".

About Bodisen Biotech, Inc.

Bodisen Biotech, Inc. is a leading manufacturer of liquid and organic compound
fertilizers, pesticides, insecticides and agricultural raw materials certified
by the Petroleum Chemical Industry Administrative office of China (Chemical
Petroleum Production Administrative Bureau), Shaanxi provincial government and
Chinese government.  The Company is headquartered in Shaanxi province and is a
Delaware Corporation.  The Company's environmentally friendly "green" products
have been proven to improve soil and plant quality and increase crop yields.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995.  These statements are based on the current expectations or beliefs of
Bodisen Biotech, Inc. management and are subject to a number of factors and
uncertainties, and the outcome of events may differ materially from those
described in the forward-looking statements.

Investor Relations:

info@bodisen.com

Enquiries:

Charles Stanley Securities (Nominated Adviser)

Philip Davies / Carl Holmes - 0207 149 6000




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCDZLBFDVBXBBF

Bodisen Biotech (LSE:BODI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Bodisen Biotech (LSE:BODI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024